Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 9
1976 31
1977 36
1978 52
1979 53
1980 72
1981 114
1982 75
1983 79
1984 74
1985 65
1986 67
1987 85
1988 86
1989 71
1990 67
1991 57
1992 74
1993 103
1994 64
1995 55
1996 55
1997 68
1998 87
1999 73
2000 80
2001 64
2002 56
2003 78
2004 74
2005 73
2006 92
2007 101
2008 120
2009 82
2010 88
2011 117
2012 109
2013 114
2014 114
2015 111
2016 112
2017 137
2018 132
2019 131
2020 167
2021 182
2022 174
2023 167
2024 197
2025 255
2026 124

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,611 results

Results by year

Filters applied: . Clear all
Page 1
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, Frick G, Gault L, Howard JF Jr; CHAMPION MG Study Group. Meisel A, et al. J Neurol. 2023 Aug;270(8):3862-3875. doi: 10.1007/s00415-023-11699-x. Epub 2023 Apr 27. J Neurol. 2023. PMID: 37103755 Free PMC article. Clinical Trial.
INTRODUCTION: Ravulizumab demonstrated efficacy and an acceptable safety profile versus placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia …
INTRODUCTION: Ravulizumab demonstrated efficacy and an acceptable safety profile versus placebo in the randomized controlled period (RCP) of …
Myasthenia gravis. Update on diagnosis and therapy.
García Estévez DA, Pardo Fernández J. García Estévez DA, et al. Med Clin (Barc). 2023 Aug 11;161(3):119-127. doi: 10.1016/j.medcli.2023.04.006. Epub 2023 May 27. Med Clin (Barc). 2023. PMID: 37248131 Review. English, Spanish.
Myasthenia gravis is an autoimmune disease caused by the presence of specific antibodies targeting different postsynaptic components of the neuromuscular junction, and is clinically characterized by the presence of fatigueable muscle weakness. ...In addition, …
Myasthenia gravis is an autoimmune disease caused by the presence of specific antibodies targeting different postsynapt …
Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
Vakrakou AG, Karachaliou E, Chroni E, Zouvelou V, Tzanetakos D, Salakou S, Papadopoulou M, Tzartos S, Voumvourakis K, Kilidireas C, Giannopoulos S, Tsivgoulis G, Tzartos J. Vakrakou AG, et al. Front Immunol. 2023 Jul 26;14:1212757. doi: 10.3389/fimmu.2023.1212757. eCollection 2023. Front Immunol. 2023. PMID: 37564637 Free PMC article. Review.
Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. ...On the other hand, acetylcholine re …
Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-mediated disease characterized …
Efgartigimod: First Approval.
Heo YA. Heo YA. Drugs. 2022 Feb;82(3):341-348. doi: 10.1007/s40265-022-01678-3. Drugs. 2022. PMID: 35179720 Free PMC article. Review.
In December 2021, intravenous efgartigimod received its first approval in the USA for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive. Intravenous efgartigimod has also been e …
In December 2021, intravenous efgartigimod received its first approval in the USA for the treatment of generalized myasthenia grav …
Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures.
Li H, Pham MC, Teng J, O'Connor KC, Noviello CM, Hibbs RE. Li H, et al. Cell. 2025 May 1;188(9):2390-2406.e20. doi: 10.1016/j.cell.2025.03.004. Epub 2025 Apr 8. Cell. 2025. PMID: 40203823 Free PMC article.
Skeletal muscle contraction is triggered by acetylcholine (ACh) binding to its ionotropic receptors (AChRs) at neuromuscular junctions. In myasthenia gravis (MG), autoantibodies target AChRs, disrupting neurotransmission and causing muscle weakness. .. …
Skeletal muscle contraction is triggered by acetylcholine (ACh) binding to its ionotropic receptors (AChRs) at neuromuscular j …
The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player?
Michailidou I, Patsiarika A, Kesidou E, Boziki MK, Parisis D, Bakirtzis C, Chroni E, Grigoriadis N. Michailidou I, et al. Front Immunol. 2025 Apr 15;16:1526317. doi: 10.3389/fimmu.2025.1526317. eCollection 2025. Front Immunol. 2025. PMID: 40303417 Free PMC article. Review.
The complement system is a key component of the innate immune system. In antiacetylcholine receptor (AChR) antibody-positive (Ab+) generalized myasthenia gravis (MG), complement activation has long been considered a principal driver of pathology. ...Th …
The complement system is a key component of the innate immune system. In antiacetylcholine receptor (AChR) antibody-positive ( …
[Muscle-Specific Receptor Tyrosine Kinase Antibody Positive Myasthenia Gravis].
Motomura M, Kitanosono H, Yoshimura S, Shiraishi H. Motomura M, et al. Brain Nerve. 2024 May;76(5):623-629. doi: 10.11477/mf.1416202652. Brain Nerve. 2024. PMID: 38741505 Review. Japanese.
Reportedly, patients with muscle-specific kinase (MuSK) antibody-positive myasthenia gravis (MG) account for approximately 3.0% of all patients with MG in Japan. Compared with patients who have acetylcholine receptor antibody-positive MG, …
Reportedly, patients with muscle-specific kinase (MuSK) antibody-positive myasthenia gravis (MG) account for approximat …
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?
Monte G, Spagni G, Damato V, Iorio R, Marino M, Evoli A. Monte G, et al. J Neurol. 2021 May;268(5):1803-1807. doi: 10.1007/s00415-020-10342-3. Epub 2021 Jan 2. J Neurol. 2021. PMID: 33387011
BACKGROUND: Anti-acetylcholine receptor antibodies (AChR Abs) are detected in 85% of myasthenia gravis (MG) patients, at higher rates in patients with late-onset disease. ...
BACKGROUND: Anti-acetylcholine receptor antibodies (AChR Abs) are detected in 85% of myasthenia gravis (M …
Pathogenesis and detection methods of anti-acetylcholine receptor antibodies in myasthenia gravis.
Suzuki S. Suzuki S. Immunol Med. 2025 Jun;48(2):117-123. doi: 10.1080/25785826.2025.2472449. Epub 2025 Feb 27. Immunol Med. 2025. PMID: 40013423 Free article. Review.
Myasthenia gravis (MG), which affects the endplate region of the postsynaptic neuromuscular junction, is the best-understood autoimmune disease. MG is driven by anti-acetylcholine receptor (AChR) or muscle-specific receptor tyrosine kinase, and …
Myasthenia gravis (MG), which affects the endplate region of the postsynaptic neuromuscular junction, is the best-understood a …
4,611 results